-
Mashup Score: 0
On November 8, 2022, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) in combination with platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
Original Article from The New England Journal of Medicine â Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
SCI member Vasu Divi and colleagues found that Neoadjuvant therapy with #cemiplimab was associated with a pathological complete response in a high percentage of patients with resectable #cutaneoussquamouscellcarcinoma. https://t.co/4WYhUklksj https://t.co/QREUlAft7f
-
-
Mashup Score: 2
Cemiplimab extended OS compared with single-agent chemotherapy for women with recurrent cervical cancer, according to randomized phase 3 study results published in The New England Journal of Medicine.Researchers characterized the OS benefit as âsignificant and clinically meaningful.â
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Cemiplimab extended OS compared with single-agent chemotherapy for women with recurrent cervical #cancer, according to randomized phase 3 study results published in @NEJM. Read here: https://t.co/NG0m15rDhu
-
-
Mashup Score: 0Study: Cemiplimab More Cost-effective Than Chemotherapy for Some Patients With NSCLC - 2 year(s) ago
An analysis concluded that cemiplimab may be more cost-effective than chemotherapy as first-line treatment for some US patients with nonâsmall cell lung cancer (NSCLC).
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Study: #Cemiplimab More Cost-effective Than Chemotherapy for Some Patients With #NSCLC https://t.co/5slCFe3lxg https://t.co/NyuGClWJS9
-
-
Mashup Score: 0
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage ColonyâStimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma #Cemiplimab #HeadAndNeck #Radiotherapy https://t.co/jxhmxr9o4U https://t.co/N71dPX2XAw
-
-
Mashup Score: 0Phase 3 Data Solidify Cemiplimabâs Role in Second-Line Treatment of Cervical Cancer - 3 year(s) ago
In May, results showed that cemiplimab (Libtayo, Regeneron/Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Phase 3 Data Solidify #Cemiplimabâs Role in Second-Line Treatment of #Cervical Cancer $REGN @SanofiUS #Libtayo https://t.co/0Ttu609bTY via @AJMC_Journal
-
-
Mashup Score: 2Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial - 3 year(s) ago
Cemiplimab exhibited clinically meaningful antitumour activity and an acceptable safety profile in patients with locally advanced basal cell carcinoma after HHI therapy.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Now in our June issue: #Cemiplimab in locally advanced #basalcellcarcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial #skincancer https://t.co/qWTFr38BIZ
-
-
Mashup Score: 2Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial - 3 year(s) ago
Cemiplimab exhibited clinically meaningful antitumour activity and an acceptable safety profile in patients with locally advanced basal cell carcinoma after HHI therapy.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New RESEARCH: #Cemiplimab in locally advanced #basalcellcarcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial #skincancer https://t.co/qWTFr2R0Rr
-
-
Mashup Score: 0
The PD-1 inhibitor cemiplimab-rwlc, sold as Libtayo, was FDA approved as a monotherapy for patients with first-line advanced nonâsmall cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
ICYMI: .@US_FDA Approves #Cemiplimab for First-Line Advanced NonâSmall Cell Lung Cancer With PD-L1 Expression https://t.co/FeRUYhvxtW https://t.co/WMY57VI82B
-
-
Mashup Score: 0This Week in Managed Care: February 26, 2021 - 3 year(s) ago
This week, the top managed care news included an FDA committee meeting on J&J’s COVID-19 vaccine; cemiplimab approved for first-line advanced nonâsmall cell lung cancer with PD-L1 expression; real-world outcomes contrast cancer clinical trial results in Medicare patients.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
This week, the top managed care news included a @US_FDA committee meeting to discuss @JNJNews' #COVID19 #vaccine; #cemiplimab approved for first-line advanced nonâsmall cell #lungcancer with PD-L1 expression. Watch This Week in Managed Care! https://t.co/BTzNmaTUmd https://t.co/SZDNBzoD5E
-
đ„đšHot off the press. @US_FDA approves #Cemiplimab-rwlc (another anti PD-1) plus #chemotherapy (in 1st line) for patients with advanced non-small cell #LungCancer. Compared with chemo alone: mOS: 21.9 vs 13 months mPFS: 8.2 vs 5 months RR: 43% vs 23% https://t.co/2tNhjycUka